STOCK TITAN

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Rhea-AI Summary
GE HealthCare acquires MIM Software to enhance its precision care strategy by integrating AI-enabled image analysis and workflow tools across multiple care areas, aiming to deliver more personalized, efficient, and connected care solutions. The addition of MIM Software's offerings strengthens GE HealthCare's response to provider needs, simplifying, streamlining, and automating essential tasks to enhance workflows.
Positive
  • None.
Negative
  • None.

The acquisition of MIM Software by GE HealthCare introduces a strategic expansion in the digital healthcare space, particularly in imaging analytics and workflow solutions. This move aligns with the broader industry trend towards digitalization and personalized healthcare, which aims to enhance patient outcomes and operational efficiency. The integration of MIM Software's capabilities with GE HealthCare's existing portfolio is likely to address the growing demand for advanced imaging and workflow automation in response to increasing procedure complexity and staffing challenges in healthcare.

From a market perspective, the transaction can be seen as a competitive maneuver to solidify GE HealthCare's market position against other major players in the medical technology field. The focus on precision care and the incorporation of AI-enabled tools across multiple care areas could potentially open new revenue streams and provide cross-selling opportunities within existing customer bases. The emphasis on end-to-end standardization may also resonate with large healthcare systems seeking comprehensive solutions, potentially leading to larger contracts and partnerships.

However, the financial impact remains speculative as the details of the transaction have not been disclosed and the expected neutrality to Adjusted EBIT in the first year indicates a short-term investment phase before realizing gains. Investors should monitor the integration process and the subsequent market adoption of the new offerings to gauge the long-term financial implications.

The acquisition of MIM Software by GE HealthCare is significant in the context of healthcare technology, particularly for the advancement of precision care. MIM Software's suite of tools, including MIM SurePlan and MIM Symphony, are designed to integrate seamlessly with existing healthcare systems, providing clinicians with enhanced capabilities in image analysis and patient management. The focus on oncology, urology, neurology and cardiology—key areas of medical treatment—underscores the potential for these technologies to impact patient care directly.

For instance, the integration of MIM Software's radiation oncology solutions with GE HealthCare's imaging portfolio could streamline treatment planning in cancer care, which is critical given the high prevalence of radiation therapy in cancer treatment protocols. Similarly, the combination of MIM Software's neuro imaging products with GE HealthCare's solutions could lead to more confident diagnoses and treatment plans for neurodegenerative diseases, an area of growing concern due to an aging population.

The transaction also suggests an investment in the future of Theranostics, an emerging field combining therapy and diagnostics, which could revolutionize personalized medicine. The potential for these integrated solutions to support the development of new treatments, including alpha therapies, may have far-reaching implications for medical research and the healthcare industry.

The financial implications of GE HealthCare's acquisition of MIM Software are multifaceted. While the immediate financial details remain undisclosed, the expectation set by the company for the acquisition to be neutral to Adjusted EBIT in the first year suggests that there will not be an immediate boost to profitability. This is not uncommon for acquisitions of this nature, as the initial integration costs and investments in scaling up operations can offset initial revenue gains.

However, the potential for the acquisition to be accretive thereafter indicates confidence in the long-term synergy and revenue growth. The focus should be on how effectively GE HealthCare can integrate MIM Software's technologies into its portfolio and capitalize on the growing demand for advanced digital healthcare solutions. Investors should consider the potential for market expansion, cost savings from streamlined operations and the ability to maintain a competitive edge through innovation when evaluating the long-term value of this acquisition.

Additionally, the use of cash on hand to fund the transaction suggests a strong liquidity position for GE HealthCare, which could be reassuring for investors concerned about the financial stability of the company post-acquisition.

  • With the addition of MIM Software, GE HealthCare aims to provide clinicians and healthcare systems with increasingly integrated and automated solutions, meeting the evolving needs of providers, and reinforcing a shared legacy of advanced patient care solutions
  • Portfolio additions include AI-enabled image analysis and workflow tools spanning multiple care areas, including oncology, urology, neurology, and cardiology

CHICAGO--(BUSINESS WIRE)-- Less than three months after signing an agreement to acquire MIM Software Inc. (“MIM Software”), GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company") (Nasdaq: GEHC) is proud to announce the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

"We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare. “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."

As patient procedures grow in number and complexity throughout a variety of care areas, today’s staffing shortages and other clinical challenges are expected to become more significant. The increasing availability of novel therapies and pace of change in healthcare further challenge healthcare leaders to drive operational efficiency, simplify patient management, and provide precise and accurate quantitative analysis of imaging data amid growing demand.

These conditions make the provision of critical information from advanced imaging, workflow and digital solutions even more essential to help enable faster, more effective treatment plans and healthcare systems.

The addition of MIM Software to GE HealthCare’s portfolio will strengthen the Company’s response to provider needs, supplying established solutions that are designed to help simplify, streamline, and automate essential tasks to enhance workflows. This includes continuing to grow MIM Software’s offerings for end-to-end standardization across large healthcare system fleets.

The result is an innovative offering of digital solutions that provide a variety of beneficial features across care areas:

Oncology: MIM Software's clinical tools – paired with GE HealthCare's imaging solutions – bring improved flexibility, automation, and efficiency to clinicians. This includes more streamlined processing, structured reporting, fast and high-quality contouring, advanced image fusion, dosimetry capabilities, easier IT integration, and remote access – helping to boost healthcare productivity and promote personalized patient care.

There is also special focus on radiation therapy and Theranostics.

Radiation therapy – a type of treatment given alone or in combination with surgery and/or chemotherapy – is administered to nearly two-thirds of all cancer patients.i The addition of MIM Software’s radiation oncology solutions to GE HealthCare’s portfolio is designed to provide clinicians with complementary interoperable solutions that can help simplify complex planning, delivering high quality while helping to reduce time to treatment.

In Theranostics, the combined portfolio aims to enhance medical research and clinical workflows to help clinicians improve patient stratification and selection, response prediction, and support the development of new treatments, including alpha therapies.

Urology: GE HealthCare’s ultrasound guidance technology combined with MIM Software’s post-processing and fusion expertise yield’s an integrated suite of prostate fusion solutions with the ability to address needs across the care pathway to support a patient's personal prostate cancer journey. This already includes GE HealthCare’s bkFusion,ii an MRI-ultrasound fusion prostate biopsy solution powered by MIM Software technology. bkFusion helps clinicians deliver effective detection rates,iii and provides fast and simple workflows designed for urologists, and flexibility to choose from a range of options for transperitoneal and transrectal prostate biopsies. Additionally, MIM Symphony provides solutions across precision prostate cancer management – helping radiologists review and report prostate MRI, and urologists and radiation oncologists plan ablation and brachytherapy treatments.

Neurology: GE HealthCare, already providing a range of solutions for neuro degenerative diseases – like Alzheimer’s Disease, Parkinson’s Disease, and more – will enhance its digital workflows with MIM Software’s neuro imaging products. This includes MIMneuro, which offers quantification solutions for dopamine transporter imaging and amyloid imaging. Collectively, this joint portfolio aims to boost clinicians’ confidence in image interpretation to support diagnosis, treatment planning, and monitoring, while supporting consistent and efficient workflows.

Cardiology: GE HealthCare has a broad presence in the cardiology care area, from imaging, patient care solutions, ultrasound, surgery, and radiopharmaceuticals in both PET and SPECT imaging. MIM Software’s cardiac solutions offer additional tools with advanced reconstruction and quantitative analysis for both PET and SPECT.

“Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare. “For the past two decades, our commitment to innovative, vendor-neutral solutions and high-quality services has earned the trust of our customers -- a principle that remains unchanged. As part of GE HealthCare, we look forward to expanding the development of advanced digital solutions and addressing complex needs today and in the future. Together, we'll strive to continue our shared legacy of enhancing patient care. We remain committed to precision care, spanning various disease states and imaging practices, from radiology to molecular imaging to radiation oncology and beyond."

For more information on GE HealthCare’s MIM Software offerings and full portfolio of solutions, please visit MIMSoftware.com. GE HealthCare will also showcase MIM Software solutions at the following global conferences:

  • European Association of Urology in Paris, France;
  • American Urological Association in San Antonio, Texas;
  • European Society for Radiotherapy and Oncology (ESTRO) in Glasgow, United Kingdom;
  • American Society of Clinical Oncology (ASCO) in Chicago, Illinois; and
  • Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Toronto, Canada.

Financial details of the transaction have not been disclosed publicly. GE HealthCare funded this transaction with cash on hand. The Company expects this transaction to be neutral to Adjusted EBITiv,v in year one and accretive thereafter.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X (formerly Twitter), and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

i Chen HHW, Kuo MT. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 2017 Jun 8;8(37):62742-62758. doi: 10.18632/oncotarget.18409. PMID: 28977985; PMCID: PMC5617545. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617545/
ii bkFusion is not available in all countries. Ask your local representative about your options.
iii Immerzeel J., Israël B., Bomers J., et al. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance–Ultrasound Fusion Guided Biopsy Using Local Anesthesia. Journal of European Urology. 2021.
iv See our latest earnings release dated February 6, 2024 for the definition of Adjusted EBIT.
v Non-GAAP finance measure

GE HealthCare Media Contact:

Margaret Steinhafel

M +1 608 381 8829

margaret.steinhafel@gehealthcare.com

GE HealthCare Investor Contact:

Carolynne Borders

M +1 631 662 4317

carolynne.borders@gehealthcare.com

Source: GE HealthCare

FAQ

What did GE HealthCare acquire to enhance its precision care strategy?

GE HealthCare acquired MIM Software to integrate AI-enabled image analysis and workflow tools across multiple care areas.

What are some of the portfolio additions included in the acquisition?

Portfolio additions include MIM SurePlan, MIM Symphony families, MIM Maestro, MIM Encore, and more.

How does the addition of MIM Software align with GE HealthCare's precision care strategy?

The addition of MIM Software aligns with GE HealthCare's precision care strategy to deliver more precise, connected, and efficient care across disease states.

What are the benefits of MIM Software's clinical tools in the oncology care area?

MIM Software's clinical tools bring improved flexibility, automation, and efficiency to clinicians in oncology care, aiding in boosting healthcare productivity and promoting personalized patient care.

What solutions does MIM Software provide in the neurology care area?

MIM Software provides neuro imaging products, including MIMneuro, offering quantification solutions for dopamine transporter imaging and amyloid imaging to support diagnosis, treatment planning, and monitoring in neuro degenerative diseases.

GE HealthCare Technologies Inc.

NASDAQ:GEHC

GEHC Rankings

GEHC Latest News

GEHC Stock Data

37.37B
424.19M
6.76%
72%
2.67%
Irradiation Apparatus Manufacturing
Manufacturing
Link
United States of America
CHICAGO

About GEHC

ge healthcare (nyse: ge) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. while we encourage and welcome comments to our linkedin page, these posts from members of the public do not necessarily represent ge healthcare views, and we do not confirm their accuracy or endorse them. ge healthcare is part of highly regulated medical device and pharmaceutical industry. posts and conversations may be removed as a result, but may be forwarded to other people within ge healthcare for follow-up as appropriate. as part of our commitment to you and to the rest of the linkedin members, we will do our best to ensure that the content on the page remains positive. however, since we cannot monitor every post or conversation feed, we realize that the occasional objectionable posts will pop up just from time to time. therefore, the company reserves the right to remove any postings at i